Allarity Therapeutics, Inc. Debt Conversion, Converted Instrument, Amount
Allarity Therapeutics, Inc. (ALLR) reported Debt Conversion, Converted Instrument, Amount of $453.00 thousand for the 9-month period ending 2023-09-30, per its 10-Q filed 2023-11-14.
Discontinued › Cash Flow › Financing Activities
us-gaap:DebtConversionConvertedInstrumentAmount1 · last filed 2023-11-14
- Allarity Therapeutics, Inc. debt conversion, converted instrument, amount for the quarter ending 2023-09-30 was $0.00, a 100.00% decline year-over-year.
- Allarity Therapeutics, Inc. debt conversion, converted instrument, amount for the quarter ending 2022-12-31 was $54.00K.
- Allarity Therapeutics, Inc. debt conversion, converted instrument, amount for the quarter ending 2022-09-30 was $402.00K.
- Allarity Therapeutics, Inc. debt conversion, converted instrument, amount for the quarter ending 2022-06-30 was $567.00K.
- Allarity Therapeutics, Inc. debt conversion, converted instrument, amount for fiscal 2022 was $1.16M, a 16428.57% increase from fiscal 2021.
- Allarity Therapeutics, Inc. debt conversion, converted instrument, amount for fiscal 2021 was $7.00K.
| Period end | Debt Conversion, Converted Instrument, Amount 3 month | Debt Conversion, Converted Instrument, Amount 3 month as first filed | Debt Conversion, Converted Instrument, Amount 6 month | Debt Conversion, Converted Instrument, Amount 9 month | Debt Conversion, Converted Instrument, Amount 12 month | Debt Conversion, Converted Instrument, Amount 12 month as first filed |
|---|---|---|---|---|---|---|
| 2023-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-14 | $453.00K 10-Q · filed 2023-11-14 | ||||
| 2023-06-30 | $453.00K 10-Q · filed 2023-08-14 | |||||
| 2022-12-31 | $54.00K derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-13 | $456.00K derived: sum of 2 quarters · filed 2023-03-13 | $1.02M derived: sum of 3 quarters · filed 2023-03-13 | $1.16M 10-K · filed 2023-03-13 | ||
| 2022-09-30 | $402.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-14 | $969.00K derived: sum of 2 quarters · filed 2022-11-14 | $1.10M 10-Q · filed 2022-11-14 | |||
| 2022-06-30 | $567.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2022-10-07 | $701.00K 10-Q · filed 2022-10-07 | ||||
| 2022-03-31 | $134.00K 10-Q · filed 2023-05-11 | $381.00K 10-Q · filed 2022-05-27 | ||||
| 2021-12-31 | $7.00K 10-K · filed 2023-03-13 | $82.00K 10-K · filed 2022-05-17 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| PALATIN TECHNOLOGIES INC (PTN) | United States | $0.017B | -5.36 |
| Lipocine Inc. (LPCN) | United States | $0.017B | -1.79 |
| Pasithea Therapeutics Corp. (KTTA) | United States | $0.017B | -0.81 |
| Biofrontera Inc. (BFRI) | United States | $0.018B | -2.13 |
| Korsana Biosciences, Inc. (CYCN) | United States | $0.016B | |
| Citius Pharmaceuticals, Inc. (CTXR) | United States | $0.016B | -133.06 |
| Rocket One Inc. (RKTO) | United States | $0.019B | |
| Lantern Pharma Inc. (LTRN) | United States | $0.015B | -2.87 |
| Shuttle Pharmaceuticals Holdings, Inc. (SHPH) | United States | $0.019B | -0.31 |
| Anebulo Pharmaceuticals, Inc. (ANEB) | United States | $0.015B |